Therapeutic blocking antibodies and anti-sense oligonucleotides targeting ANGPTL3 reduce atherogenic lipoprotein levels and decrease the odds of developing cardiovascular disease in humans (38, 39), supporting ANGPTL family of proteins as druggable targets. This evidence concerns the gene ANGPTL3 and cardiovascular disorder.